{"id":"tacrolimus-ointment-0-1","safety":{"commonSideEffects":[{"rate":"10-50","effect":"Burning or stinging sensation at application site"},{"rate":"5-15","effect":"Pruritus"},{"rate":"5-10","effect":"Erythema"},{"rate":"5-10","effect":"Skin irritation"},{"rate":"1-5","effect":"Folliculitis"}]},"_chembl":null,"_dailymed":{"setId":"43b38551-6c5e-48a4-a453-9286f1c16b34","title":"TACROLIMUS (TACROLIMUS OINTMENT 0.1%) OINTMENT [ENCUBE ETHICALS, INC.]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Tacrolimus binds to the immunophilin FKBP12 and inhibits calcineurin phosphatase, preventing dephosphorylation and nuclear translocation of NFAT (nuclear factor of activated T cells). This blocks the transcription of pro-inflammatory cytokines (IL-2, TNF-α, IFN-γ) produced by T lymphocytes, thereby reducing the inflammatory response in atopic dermatitis and other inflammatory skin conditions.","oneSentence":"Tacrolimus is a calcineurin inhibitor that suppresses T-cell activation and cytokine production to reduce skin inflammation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:22:11.084Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Atopic dermatitis (eczema)"},{"name":"Other inflammatory skin conditions (off-label use in vitiligo, psoriasis, lichen planus)"}]},"trialDetails":[{"nctId":"NCT07437534","phase":"PHASE4","title":"Comparative Evaluation of the Safety and Effectiveness of Crisaborole Ointment (2%) Versus Tacrolimus Ointment (0.1%) for the Topical Treatment of Atopic Dermatitis","status":"NOT_YET_RECRUITING","sponsor":"Hayat Abad Medical Complex, Peshawar","startDate":"2026-03-01","conditions":"Atopic Dermatitis","enrollment":148},{"nctId":"NCT07307534","phase":"NA","title":"Nevus Removal vs. Conservative Treatment in Halo Nevus With Vitiligo: A Randomized Study","status":"NOT_YET_RECRUITING","sponsor":"Xijing Hospital","startDate":"2026-01-20","conditions":"Vitiligo, Halo Nevus","enrollment":60},{"nctId":"NCT06362005","phase":"PHASE4","title":"The Efficacy of Selenium as an Alternative or Complementary Topical Treatment of Oral Lichen Planus","status":"COMPLETED","sponsor":"Al-Azhar University","startDate":"2024-05-01","conditions":"Lichen Planus, Oral","enrollment":50},{"nctId":"NCT07162896","phase":"PHASE3","title":"Crisaborole 2% Versus Tacrolimus 0.1% in Children With Mild to Moderate Atopic Dermatitis","status":"NOT_YET_RECRUITING","sponsor":"Shalamar Institute of Health Sciences","startDate":"2026-06","conditions":"Atopic Dermatitis, Atopic Dermatitis (AD)","enrollment":66},{"nctId":"NCT06591884","phase":"PHASE1, PHASE2","title":"Evaluation of the Efficacy of 0.08% Tacrolimus Nanoencapsulated Aqueous Solution Spray Vs. 0.1% Free Tacrolimus Commercial Ointment in the Treatment of Oral Lichen Planus","status":"RECRUITING","sponsor":"Hospital de Clinicas de Porto Alegre","startDate":"2024-09-03","conditions":"Oral Erosive Lichen Planus","enrollment":46},{"nctId":"NCT04056962","phase":"PHASE2","title":"Tacrolimus for the Treatment of Superficial Kaposiform Hemangioendothelioma and Tufted Angioma","status":"RECRUITING","sponsor":"West China Hospital","startDate":"2019-09-01","conditions":"Tacrolimus, Kaposiform Hemangioendothelioma, Tufted Angioma","enrollment":50},{"nctId":"NCT06348602","phase":"PHASE1, PHASE2","title":"Evaluation of Safety & Efficacy for the Prevention of Ocular GVHD With Ophthalmic Tacrolimus vs Cyclosporine in Allo-HSCT","status":"RECRUITING","sponsor":"Hospital Universitario Dr. Jose E. Gonzalez","startDate":"2023-08-01","conditions":"Ocular Graft-versus-host Disease","enrollment":60},{"nctId":"NCT06035614","phase":"NA","title":"Efficacy and Safety of 308-nm Excimer Lamp Combined With Tacrolimus vs Tacrolimus as Monotherapy in Treating Vitiligo on Children","status":"COMPLETED","sponsor":"Clarteis","startDate":"2022-10-01","conditions":"Vitiligo, Pediatric ALL, Dermatologic Disease","enrollment":50},{"nctId":"NCT03614221","phase":"PHASE2","title":"Comparison of Lindioil (Indigo Naturalis Oil Extract) Ointment to Protopic® Ointment 0.1% in Treating Atopic Dermatitis","status":"COMPLETED","sponsor":"Chang Gung Memorial Hospital","startDate":"2019-06-03","conditions":"Atopic Dermatitis","enrollment":22},{"nctId":"NCT04440371","phase":"NA","title":"Phototherapy Combination With Topicals in Vitiligo","status":"UNKNOWN","sponsor":"Jordan University of Science and Technology","startDate":"2020-06-21","conditions":"Vitiligo, Generalized","enrollment":40},{"nctId":"NCT04541290","phase":"PHASE1, PHASE2","title":"Tacrolimus as Treatment of Breast Cancer-Related Lymphedema","status":"COMPLETED","sponsor":"Odense University Hospital","startDate":"2020-09-22","conditions":"Breast Cancer Lymphedema","enrollment":20},{"nctId":"NCT04706559","phase":"NA","title":"Efficacy of Oral Supplementation of Probiotics in Children With Atopic Dermatitis","status":"COMPLETED","sponsor":"B.P. Koirala Institute of Health Sciences","startDate":"2021-01-03","conditions":"Atopic Dermatitis","enrollment":98},{"nctId":"NCT04114097","phase":"PHASE4","title":"The Effects of Topical Corticosteroid Use on Insulin Sensitivity and Bone Turnover","status":"COMPLETED","sponsor":"Jacob Thyssen","startDate":"2019-08-22","conditions":"Atopic Dermatitis, Atopic Eczema","enrollment":36},{"nctId":"NCT02466997","phase":"PHASE3","title":"Efficacy of Tacrolimus in Adults With Facial Non-segmental Vitiligo - VITAC","status":"COMPLETED","sponsor":"University Hospital, Bordeaux","startDate":"2016-02-23","conditions":"Vitiligo","enrollment":42},{"nctId":"NCT03152019","phase":"PHASE2","title":"Efficacy and Safety of a 0.1% Tacrolimus Nasal Ointment as a Treatment for Epistaxis in Hemorrhagic Hereditary Telangiectasia (HHT)","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2017-05-22","conditions":"Hemorrhagic Hereditary Telangiectasia (HHT)","enrollment":50},{"nctId":"NCT02601703","phase":"PHASE3","title":"To Study Generic Tacrolimus Ointment, 0.1% in the Treatment of Moderate to Severe Atopic Dermatitis (Inflammation of Skin: Itchy, Red, Swollen, and Cracked Skin)","status":"COMPLETED","sponsor":"Glenmark Pharmaceuticals Ltd. India","startDate":"2015-08","conditions":"Atopic Dermatitis","enrollment":1110},{"nctId":"NCT00762658","phase":"PHASE1","title":"A Phase I Study to Assess Novel Ointment in a Psoriasis Plaque Test","status":"COMPLETED","sponsor":"Pfizer","startDate":"2007-11-30","conditions":"Psoriasis","enrollment":12},{"nctId":"NCT03715387","phase":"PHASE2, PHASE3","title":"Tacrolimus for Malar Edema","status":"UNKNOWN","sponsor":"University of British Columbia","startDate":"2018-10-10","conditions":"Edema Face","enrollment":100},{"nctId":"NCT02680717","phase":"PHASE1","title":"Comparative Effectiveness Trial in the Treatment of Pediatric Plaque Morphea","status":"WITHDRAWN","sponsor":"Medical College of Wisconsin","startDate":"2016-03","conditions":"Scleroderma","enrollment":""},{"nctId":"NCT02004860","phase":"PHASE3","title":"Tacrolimus Ointment Interest (PROTOPIC ®) in the Maintenance Treatment of Severe Seborrheic Dermatitis","status":"COMPLETED","sponsor":"University Hospital, Rouen","startDate":"2014-01","conditions":"Severe Seborrheic Dermatitis","enrollment":120},{"nctId":"NCT03047733","phase":"NA","title":"Comparison of Cyclic On-off and Continuous Excimer Laser Treatment for Vitiligo","status":"COMPLETED","sponsor":"Ajou University School of Medicine","startDate":"2015-07-21","conditions":"Dermatologic Disease, Vitiligo","enrollment":12},{"nctId":"NCT01544842","phase":"NA","title":"Tacrolimus Ointment in Oral Lichen Planus","status":"TERMINATED","sponsor":"University of Oulu","startDate":"2004-08","conditions":"Oral Lichen Planus","enrollment":28},{"nctId":"NCT01053247","phase":"PHASE3","title":"Study of 0416 Ointment in the Treatment of Atopic Dermatitis","status":"COMPLETED","sponsor":"Fougera Pharmaceuticals Inc.","startDate":"2008-01","conditions":"Atopic Dermatitis","enrollment":793},{"nctId":"NCT00667056","phase":"PHASE4","title":"Study of the Safety and Efficacy of Tacrolimus Ointment in Treating Chronic Allergic Contact Dermatitis","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2004-07","conditions":"Dermatitis","enrollment":98},{"nctId":"NCT00560378","phase":"PHASE3","title":"Long-term Safety of Protopic in Atopic Eczema","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"1998-06","conditions":"Dermatitis, Atopic, Eczema, Atopic","enrollment":789},{"nctId":"NCT00534508","phase":"PHASE2","title":"Distribution of Tacrolimus in Skin, Atopic Dermatitis","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2000-12","conditions":"Dermatitis, Atopic","enrollment":14},{"nctId":"NCT00480610","phase":"PHASE3","title":"Treatment and Control of Atopic Dermatitis With 0.1% Tacrolimus Ointment","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2004-04","conditions":"Dermatitis, Atopic","enrollment":226},{"nctId":"NCT00801957","phase":"PHASE2","title":"Equivalence of the Response to Vaccination of Tacrolimus Ointment to a Steroid Ointment Regimen in Children With Atopic Dermatitis","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2003-03","conditions":"Atopic Dermatitis","enrollment":260},{"nctId":"NCT01841008","phase":"PHASE2, PHASE3","title":"Maintenance Treatment of Non Segmental Vitiligo With Tacrolimus Ointment 0.1% Versus Control","status":"TERMINATED","sponsor":"Centre Hospitalier Universitaire de Nice","startDate":"2011-12","conditions":"Pigmentation Disorders, Vitiligo","enrollment":35},{"nctId":"NCT00690105","phase":"PHASE4","title":"Protopic Ointment in Adult Atopic Eczema of the Face","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2004-02","conditions":"Dermatitis, Atopic","enrollment":577},{"nctId":"NCT00523952","phase":"PHASE3","title":"Clinical Trial to Assess the Efficacy and Safety of Tacrolimus Ointment Treatment of Atopic Dermatitis in Adult Patients","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2004-01","conditions":"Dermatitis, Atopic","enrollment":303},{"nctId":"NCT00691145","phase":"PHASE3","title":"Study to Evaluate the Efficacy and Safety of 0.1% and 0.03% Tacrolimus Ointment Administered in Adults With Moderate to Severe Atopic Dermatitis","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2002-10","conditions":"Dermatitis, Atopic","enrollment":350},{"nctId":"NCT00833079","phase":"PHASE1","title":"Bioequivalence of Two Tacrolimus 0.1% Topical Ointment Formulations in Patients With Atopic Dermatitis","status":"COMPLETED","sponsor":"Sun Pharmaceutical Industries, Inc.","startDate":"2008-10","conditions":"Atopic Dermatitis","enrollment":500},{"nctId":"NCT01702181","phase":"PHASE1","title":"A Safety Study to Evaluate the Use and Effectiveness of a Topical Ointment to Treat Adults With Atopic Dermatitis","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2012-08","conditions":"Atopic Dermatitis","enrollment":92},{"nctId":"NCT01828879","phase":"PHASE4","title":"An Efficacy and Safety Study of Tacrolimus Ointment in Adult Participants With Atopic Dermatitis","status":"COMPLETED","sponsor":"Janssen-Cilag Ltd.,Thailand","startDate":"2007-11","conditions":"Dermatitis, Atopic","enrollment":74},{"nctId":"NCT01333410","phase":"PHASE4","title":"Comparison of Efficacy and Safety of 0.1% Tacrolimus and 0.1% Mometasone Furoate for Adult Vitiligo","status":"UNKNOWN","sponsor":"Mahidol University","startDate":"2009-06","conditions":"Vitiligo","enrollment":30},{"nctId":"NCT01388517","phase":"PHASE4","title":"Clinical Trial of 0.0003% Calcitriol, 0.1% Tacrolimus, and Petrolatum for the Treatment of Pityriasis Alba","status":"COMPLETED","sponsor":"Universidad Autonoma de San Luis Potosí","startDate":"2008-01","conditions":"Pityriasis Alba","enrollment":39},{"nctId":"NCT01591070","phase":"PHASE4","title":"Proactive Treatment of Tacrolimus Ointment for Adult Facial Seborrheic Dermatitis","status":"COMPLETED","sponsor":"Pusan National University Hospital","startDate":"2010-11","conditions":"Seborrheic Dermatitis","enrollment":104},{"nctId":"NCT01320579","phase":"PHASE2","title":"Investigation of the Efficacy of 2.5% and 5% Cis-urocanic Acid in Patients With Moderate or Severe Atopic Dermatitis","status":"COMPLETED","sponsor":"BioCis Pharma Ltd","startDate":"2011-03","conditions":"Atopic Dermatitis","enrollment":159},{"nctId":"NCT01233570","phase":"PHASE2","title":"Topical Tacrolimus 0.1% Ointment For Treatment Of Cutaneous Crohn's Disease","status":"COMPLETED","sponsor":"University of Aberdeen","startDate":"","conditions":"Crohn Disease","enrollment":20},{"nctId":"NCT01068054","phase":"PHASE2, PHASE3","title":"Efficacy Study of FK-506 and Cyclosporine in Vernal Keratoconjunctivits (VKC)","status":"COMPLETED","sponsor":"Siriraj Hospital","startDate":"2003-06","conditions":"Keratoconjunctivitis, Vernal","enrollment":24},{"nctId":"NCT00807690","phase":"PHASE3","title":"Vitiligo Treated With TL01 Combined With Tacrolimus Ointment Versus Placebo","status":"COMPLETED","sponsor":"Oslo University Hospital","startDate":"2005-11","conditions":"Vitiligo","enrollment":""},{"nctId":"NCT00779792","phase":"PHASE4","title":"Efficacy of Glycerol, Two Topical Steroids, and a Topical Immune Modulator Against Skin Irritation","status":"UNKNOWN","sponsor":"Odense University Hospital","startDate":"2008-09","conditions":"Dermatitis, Contact, Dermatitis, Occupational","enrollment":36},{"nctId":"NCT00134394","phase":"PHASE2","title":"Etanercept With Tacrolimus for Psoriasis","status":"COMPLETED","sponsor":"University of Medicine and Dentistry of New Jersey","startDate":"2005-02","conditions":"Psoriasis","enrollment":20},{"nctId":"NCT00236106","phase":"PHASE4","title":"Short Term Growth in Children With Atopic Dermatitis","status":"COMPLETED","sponsor":"Children´s Clinic, Randers","startDate":"2005-02","conditions":"Atopic Dermatitis","enrollment":20}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":79,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Protopic","Protopic® 0.1%","Protopic 0.1%"],"phase":"marketed","status":"active","brandName":"tacrolimus ointment 0.1%","genericName":"tacrolimus ointment 0.1%","companyName":"Hospital de Clinicas de Porto Alegre","companyId":"hospital-de-clinicas-de-porto-alegre","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Tacrolimus is a calcineurin inhibitor that suppresses T-cell activation and cytokine production to reduce skin inflammation. Used for Atopic dermatitis (eczema), Other inflammatory skin conditions (off-label use in vitiligo, psoriasis, lichen planus).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}